American Journal of Cardiology
Volume 104, Issue 8 , Pages 1035-1040 , 15 October 2009

Erythropoietin to Augment Myocardial Salvage Induced by Coronary Thrombolysis in Patients With ST Segment Elevation Acute Myocardial Infarction

  • Azan S. Binbrek, MD

      Affiliations

    • Rashid Hospital, Dubai, United Arab Emirates
    • ,
  • Nayan S. Rao, MD

      Affiliations

    • Rashid Hospital, Dubai, United Arab Emirates
    • ,
  • Najib Al Khaja, MD

      Affiliations

    • Rashid Hospital, Dubai, United Arab Emirates
    • ,
  • Jamal Assaqqaf, MB

      Affiliations

    • Rashid Hospital, Dubai, United Arab Emirates
    • ,
  • Burton E. Sobel, MD

      Affiliations

    • University of Vermont, Burlington, Vermont
    • Corresponding Author InformationCorresponding author: Tel: 802-656-8955; fax: 802-656-8957

Received 9 April 2009 ,Revised 20 May 2009 ,Accepted 20 May 2009.

References 

  1. Binbrek AS, Rao NS, Neimane D, Hatou E, Abdulali S, Sobel BE. Comparison of rapidity of coronary recanalization in men with tenecteplase versus alteplase in acute myocardial infarction. Am J Cardiol. 2004;93:1465–1468
  2. Roberts R, Henry PD, Sobel BE. An improved basis for enzymatic estimation of infarct size. Circulation. 1975;52:743–754
  3. Abendschein DR, Ellis AK, Eisenberg PR, Klocke FJ, Sobel BE, Jaffe AS. Prompt detection of coronary recanalization by analysis of rates of change of concentrations of macromolecular markers in plasma. Coron Artery Dis. 1991;2:201–212
  4. Bullard AJ, Yellon DM. Chronic erythropoietin treatment limits infarct-size in the myocardium in vitro. Cardiovasc Drugs Ther. 2005;19:333–336
  5. Chan CY, Chen YS, Lee HH, Huang HS, Lai YL, Chen CF, et al. Erythropoietin protects post-ischemic hearts by preventing extracellular matrix degradation: role of Jak2-ERK pathway. Life Sci. 2007;81:717–723
  6. Moon C, Krawczyk M, Ahn D, Ahmet I, Paik D, Lakatta EG, et al. Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. Proc Natl Acad Sci U S A. 2003;100:11612–11617
  7. Nishihara M, Miura T, Miki T, Sakamoto J, Tanno M, Kobayashi H, et al. Erythropoietin affords additional cardioprotection to preconditioned hearts by enhanced phosphorylation of glycogen synthase kinase-3 beta. Am J Physiol Heart Circ Physiol. 2006;291:H748–H755
  8. Parsa CJ, Kim J, Riel RU, Pascal LS, Thompson RB, Petrofski JA, et al. Cardioprotective effects of erythropoietin in the reperfused ischemic heart: a potential role for cardiac fibroblasts. J Biol Chem. 2004;279:20655–20662
  9. Parsa CJ, Matsumoto A, Kim J, Riel RU, Pascal LS, Walton GB, et al. A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest. 2003;112:999–1007
  10. Prunier F, Pfister O, Hadri L, Liang L, Del Monte F, Liao R, et al. Delayed erythropoietin therapy reduces post-MI cardiac remodeling only at a dose that mobilizes endothelial progenitor cells. Am J Physiol Heart Circ Physiol. 2007;292:H522–H529
  11. Rui T, Feng Q, Lei M, Peng T, Zhang J, Xu M, et al. Erythropoietin prevents the acute myocardial inflammatory response induced by ischemia/reperfusion via induction of AP-1. Cardiovasc Res. 2005;65:719–727
  12. van der Meer P, Lipsic E, Henning RH, Boddeus K, van der Velden J, Voors AA, et al. Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. J Am Coll Cardiol. 2005;46:125–133
  13. Xu B, Dong GH, Liu H, Wang YQ, Wu HW, Jing H. Recombinant human erythropoietin pretreatment attenuates myocardial infarct size: a possible mechanism involves heat shock protein 70 and attenuation of nuclear factor-kappaB. Ann Clin Lab Sci. 2005;35:161–168
  14. Hanlon PR, Fu P, Wright GL, Steenbergen C, Arcasoy MO, Murphy E. Mechanisms of erythropoietin-mediated cardioprotection during ischemia-reperfusion injury: role of protein kinase C and phosphatidylinositol 3-kinase signaling. FASEB J. 2005;19:1323–1325
  15. Kristensen J, Maeng M, Rehling M, Berg JS, Mortensen UM, Nielsen SS, et al. Lack of acute cardioprotective effect from preischaemic erythropoietin administration in a porcine coronary occlusion model. Clin Physiol Funct Imaging. 2005;25:305–310
  16. Lipsic E, van der Meer P, Henning RH, Suurmeijer AJ, Boddeus KM, van Veldhuisen DJ. Timing of erythropoietin treatment for cardioprotection in ischemia/reperfusion. J Cardiovasc Pharmacol. 2004;44:473–479
  17. Binbrek AS, Mittal B, Rao KN, Sobel BE. The potential of erythropoietin for conferring cardioprotection complementing reperfusion. Coron Artery Dis. 2007;18:583–585
  18. REVEAL: Reduction of Infarct Expansion and Ventricular Remodeling With Erythropoietin After Large Myocardial Infarction. http://clinicaltrials.gov/ct2/show/NCT00378352Accessed March 9, 2009
  19. Efficacy Study of Erythropoietin After Revascularization in Myocardial Infarction (REVIVAL-3). http://clinicaltrials.gov/ct2/show/NCT00390832Accessed March 9, 2009
  20. Hale SL, Sesti C, Kloner RA. Administration of erythropoietin fails to improve long-term healing or cardiac function after myocardial infarction in the rat. J Cardiovasc Pharmacol. 2005;46:211–215
  21. Ruvinov E, Sharabani-Yosef O, Nagler A, Einbinder T, Feinberg MS, Holbova R, et al. Transplantation of genetically engineered cardiac fibroblasts producing recombinant human erythropoietin to repair the infarcted myocardium. Fibrogenesis Tissue Repair. 2008;1:7
  22. Westenbrink BD, Lipsic E, van der Meer P, van der Harst P, Oeseburg H, Du Marchie Sarvaas GJ, et al. Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization. Eur Heart J. 2007;28:2018–2027
  23. Ito WD, Schaarschmidt S, Klask R, Hansen S, Schafer HJ, Mathey D, et al. Infarct size measurement by triphenyltetrazolium chloride staining versus in vivo injection of propidium lodide. J Mol Cell Cardiol. 1997;29:2169–2175
  24. Kjekshus JK, Sobel BE. Depressed myocardial creatine phosphokinase activity following experimental myocardial infarction in rabbit. Circ Res. 1970;27:403–414
  25. Maroko PR, Kjekshus JK, Sobel BE, Watanabe T, Covell JW, Ross J, et al. Factors influencing infarct size following experimental coronary artery occlusions. Circulation. 1971;43:67–82
  26. Shell WE, Kjekshus JK, Sobel BE. Quantitative assessment of the extent of myocardial infarction in the conscious dog by means of analysis of serial changes in serum creatine phosphokinase activity. J Clin Invest. 1971;50:2614–2625
  27. Beguin Y. Erythropoietin and platelet production. Haematologica. 1999;84:541–547
  28. French CF, Zaman AKMT, Sobel BE. Failure of erythropoietin to render jeopardized ischemic myocardium amenable to incremental salvage by early reperfusion. Coron Artery Dis. 2009;20:295–299
  29. Rao KNS, Binbrek AS, Sobel BE. Heart disease and erythropoietin—a perspective. Future Cardiol. 2008;4:57–64

 This study was partly supported by a Shaikh Hamdan Bin Rashed Al Maktoum Award (Dubai, United Arab Emirates).

PII: S0002-9149(09)01169-2

doi: 10.1016/j.amjcard.2009.05.050

American Journal of Cardiology
Volume 104, Issue 8 , Pages 1035-1040 , 15 October 2009

Article Tools

* Image Usage & Resolution